PDCD1 and neoplasm: In another study, Winograd et al.[149] by using a combination of gemcitabine/nab-paclitaxel plus anti-PD-1 and anti-CD40 mAbs observed regression of the tumor mass and an improved median overall survival of tumor-bearing mice.